ImmuPharma plc (LON:IMM – Get Free Report) traded up 3.4% on Friday . The company traded as high as GBX 4.70 and last traded at GBX 4.70. 729,994 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 3,742,107 shares. The stock had previously closed at GBX 4.55.
ImmuPharma Stock Performance
The company has a 50 day moving average of GBX 6.76 and a 200-day moving average of GBX 8.33. The stock has a market cap of £27.45 million, a price-to-earnings ratio of -6.13 and a beta of 3.02.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
